To include your compound in the COVID-19 Resource Center, submit it here.

Seres falls on SER-287 clinical response rates in UC

Microbiome company Seres Therapeutics Inc. (NASDAQ:MCRB) fell $3.74 (23%) to $12.30 on Monday after reporting that none of three SER-287 treatment regimens improved the secondary endpoint of clinical response rate compared to placebo in a Phase Ib trial to treat ulcerative colitis. The company said that it plans to meet

Read the full 503 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE